Neurotoxicity

Peripheral neurotoxicity occurs in approximately 40 percent of previously untreated cancer patients who receive chemotherapy regimens containing taxane. Because the effects of this therapy may limit treatment for a significant percentage of patients, it is essential for researchers to have access to study models that can mimic taxane toxicity. Charles River conducts contract studies in an established animal model of neurotoxicity to test the efficacy of novel therapeutics.

Scientific Resources

Electronic Versions of our Posters from AACR 2017 Now Available

View Posters »

You may also be interested in...

Imaging Services

Our range of imaging modalities can dramatically increase the efficiency and significantly enhance the value of your in vivo study.

Translational Tools

Our range of imaging and biomarker services helps enhance the overall scientific understanding of your compound.